A cohort study comparing the effects of medical cannabis for anxiety patients with and without comorbid sleep disturbance
Open Access
- 28 December 2023
- journal article
- research article
- Published by Wiley in Neuropsychopharmacology Reports
- Vol. 44 (1) , 129-142
Abstract
Background: Research on cannabis‐based medicinal products (CBMPs) in anxiety remains inconclusive due to a paucity of high‐quality evidence. Studies indicate a bidirectional relationship between generalized anxiety disorder (GAD) and sleep disruption, but it is unclear how this affects CBMP treatment outcomes. This study aims to compare the patient‐reported outcome measures (PROMs) of patients prescribed CBMPs for GAD, with and without impaired sleep.Methods: Changes in PROMs were recorded from baseline to 1, 3, 6, and 12 months between those with impaired or unimpaired sleep. Multivariate logistic regression was applied to compare factors associated with a clinically significant improvement in GAD‐7 at 12 months. Secondary outcomes included adverse event incidence and frequency.Results: Of the 302 patients that fit the inclusion criteria, mean GAD‐7, single‐item sleep quality, and EQ‐5D‐5L index values improved at all time points (p < 0.001). A relationship between sleep impairment and clinically significant changes in GAD‐7 at 1 and 3 months was identified (p ≤ 0.01). On multivariate regression, only baseline GAD severity was associated with an increased likelihood of observing a clinically significant improvement in anxiety (p < 0.001). Seven hundred and seven (234%) adverse events were reported by 55 (18.21%) participants.Conclusions: This study observed an association between CBMP treatment and improvements in anxiety in patients with GAD. While patients with comorbid sleep disruption had greater improvements in anxiety, the differences were not maintained in a multivariate analysis. Baseline anxiety severity may be a predictor for CBMP treatment outcomes.Keywords
This publication has 80 references indexed in Scilit:
- Cost of disorders of the brain in Europe 2010European Neuropsychopharmacology, 2011
- Getting carried away: a note showing baseline observation carried forward (BOCF) results can be calculated from published complete-cases resultsInternational Journal of Obesity, 2011
- An Evidence-Based Review of Acute and Long-Term Effects of Cannabis Use on Executive Cognitive FunctionsJournal of Addiction Medicine, 2011
- Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naïve Social Phobia PatientsNeuropsychopharmacology, 2011
- Opposite Effects of Δ-9-Tetrahydrocannabinol and Cannabidiol on Human Brain Function and PsychopathologyNeuropsychopharmacology, 2009
- The Neurobiology of Anxiety Disorders: Brain Imaging, Genetics, and PsychoneuroendocrinologyPsychiatric Clinics of North America, 2009
- Cognitive Behavioral Therapy, Sertraline, or a Combination in Childhood AnxietyNew England Journal of Medicine, 2008
- Cognitive Factors that Maintain Social Anxiety Disorder: a Comprehensive Model and its Treatment ImplicationsCognitive Behaviour Therapy, 2007
- A Brief Measure for Assessing Generalized Anxiety DisorderArchives of internal medicine (1960), 2006
- CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatmentSeminars in Radiation Oncology, 2003